Amgen Inc.'s first quarter 2018 revenue increased 2% from the year-prior quarter to $5.6 billion. Net income came in 12% higher at $2.3 billion.
New and recent launches, including Repatha (evolocumab), Kyprolis (carfilzomib), Prolia (denosumab) and Xgeva (denosumab) have shown double-digit growth.
